Search

Search Constraints

You searched for: Author/Creator Lin, Simeng

Search Results

1. Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients. (2nd September 2021)

2. Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab. Issue 5 (22nd March 2021)

3. Clinical Features and Genetic Risk of Demyelination Following Anti-TNF Treatment. (4th May 2020)

4. Implications for sequencing of biologic therapy and choice of second anti‐TNF in patients with inflammatory bowel disease: results from the IMmunogenicity to Second Anti‐TNF therapy (IMSAT) therapeutic drug monitoring study. Issue 8 (29th August 2022)

5. Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. Issue 10 (26th April 2021)

7. Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study. (February 2023)

10. P304 Exploring attitudes to virtual gastroenterology clinic provision in the South West: a regional staff survey. (19th June 2022)